Primary aldosteronism
Conditions
Interventions
Experimental group:SBRT in combination with MRA and/or other antihypertensive drugs
Sponsors
Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Be able to sign an informed consent form, including adherence to the requirements and limitations outlined in the Informed Consent Form (ICF) and in this protocol; 2. Provide a signed and dated written ICF prior to performing any of the study's required steps, sampling and analyses; 3. Confirm the diagnosis of primary aldosteronism (PA) in strict accordance with the consensus of the 2020 European Society of Hypertension Working Group on Endocrine Hypertension, "Staging Diagnosis, Treatment, Complications, and Future Directions for Research in Primary Aldosteronism"; and from these, screen patients with PA who are unable or unwilling to undergo surgical intervention, who do not tolerate or refuse pharmacological therapy, or who have Patients with PA who have failed AVS. 4. Age 18-70 years old, gender is not limited.
Exclusion criteria
Exclusion criteria: 1. Primary hypertension or other secondary hypertensive disorders such as renal artery stenosis, pheochromocytoma or Cushing's syndrome; 2. Those whose elevated blood pressure is unable to reach 160/100 or less after aggressive medication; 3. Women who are pregnant or breastfeeding; 4. Oral contraceptives or oestrogen replacement therapy; 5. Combination of other malignancies; 6. Any psychiatric illness, severe or unstable known disease that, in the opinion of the investigator, may affect the conduct of the study or the safety or outcome determination of the trial, including, but not limited to, severe respiratory disease, cardiovascular disease (including, but not limited to, symptomatic congestive heart failure, myocardial infarction, coronary artery disease, severe arrhythmia, deep vein thrombosis, clinically significant vascular disease, etc.; patients suffering from immune deficiency diseases; 7. History of previous adrenal or abdominal surgery; 8. Patients suffering from contraindications to radiotherapy. 9. Participation in other clinical trials within the last month. 10. Known alcohol or drug dependence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of hypertension control; | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of control of biochemical indicators;Treatment-related adverse events; | — |
Countries
China
Contacts
Public ContactWenhui Li
Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)
Outcome results
None listed